We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At week 48, 58.7% of guselkumab IV induction ...

TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of ...

The lowest effective recommended dosage should be used to maintain therapeutic response. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients ...

Please provide your email address to receive an email when new articles are posted on . Automated syringe pump induction may be associated with less propofol waste after IV anesthesia vs. manual ...

Findings at week 12 showed a significantly greater proportion of patients treated with the SC induction regimen achieved clinical remission compared with those who received placebo. The Food and Drug ...

In May, Johnson & Johnson touted the success of its intravenous (IV) formulation of Tremfya in two head-to-head trials against its own Stelara in Crohn’s disease. A month later, a subcutaneous (SC) ...

The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV ...

Johnson & Johnson received approval for a subcutaneous induction regimen of Tremfya to treat ulcerative colitis from the Food and Drug Administration. The pharmaceutical giant said Friday it now ...